Merieux Equity Partners

Thierry CHIGNON and Jean Chatillon will be representing Merieux Equity Partners  at #SuperInvestor in Monaco next week. Thierry will also be chairing the panel on “Different routes to accessing opportunities in the mid-market” on 6 November. This session will dive deep into the evolving landscape of mid-market investments, covering both private equity and private debt. Thierry and the panel will explore how managers are standing out, the benefits of true sector specialisation, and the role of operational value-add in driving success. 🗓 Wednesday, 6 November 2024 ⏰ 2:00 pm - 2:30 pm 📍 Main Stage #superinvestor #privateequity #midmarket #healthcare #Buyout #investment

Read about Merieux Innovation 2, Merieux Equity Partners’ second venture fund currently raising in Mergermarket this week, including how we continue to see attractive opportunities in healthcare across our Innovation and Buyout strategies. 👉 Read the full article here : https://lnkd.in/esmxKicg #healthcare #venture #innovation #investment #Buyout #fundraising

We are grateful to all our international investors (institutional and family offices) and portfolio CEOs who participated to our Merieux Equity Partners Innovation AGM in Paris yesterday. Key highlights of the day: 🔹 Very active past 12 months, including the successful exit of Mablink, two new investments (CorFlow and Prothea), and numerous achievements across our portfolio. 🔹 Strengthening of the Innovation investment team with key additions: Kristin Thompson as Investment Director, Jean-Guillaume Lafay as Operating Partner and Didier Deltort as Senior Advisor. 🔹 Highly active in Value Creation: Our portfolio companies benefit from a unique variety of support through our operating capabilities (Operating Partners, Senior Advisors, Mérieux Group networks, etc.). 🔹 Strong ambitions for the year ahead with the launch of exciting new projects. Thanks to our trustful Limited Partners, we support visionary and ambitious entrepreneurs in healthcare innovation, accelerating access to products and services with a transformative impact on patients. Valérie Calenda Yoann Bonnamour Jonathan Dupont Guillaume Thoviste Kristin Thompson Andrea Ottavis

Private Equity in France 2024 Preqin : Driving innovation and growth The private equity landscape in France is evolving rapidly, with healthcare, technology, and renewable energy leading the charge. In 2023 alone, French managers raised an impressive €21.5 billion, positioning the country as a hub for strategic investments. Initiatives like France 2030 are paving the way for significant growth, both domestically and internationally. For Valérie Calenda, Managing Partner at Merieux Equity Partners: "We are particularly excited about France's thriving healthtech sector. Investors who can identify and accelerate innovative companies with transformative technologies will create the most value for their LPs." With a focus on ESG and impact-driven investments, the opportunities in healthtech and life sciences are vast and ready for those willing to seize them. This factsheet, produced by Preqin, provides comprehensive insights into the trends shaping private equity in France for 2024 and beyond. Discover how France's private equity sector is setting the stage for transformative investments in 2024 Download the full report  👉 https://lnkd.in/eeyeSt5F #PrivateEquity #France #buyout #Innovation #HealthCare #ESG

Broken String Biosciences strengthens its governance to accelerate its growth🚀 We’re proud to announce that Laurence Reid, PhD (former CEO of Decibel Therapeutics) has joined as Chairman, and Brad Crutchfield (former Chief Commercial Officer of 10x Genomics) as Non-Executive Director. Their combined expertise in biotech, life sciences, and scaling commercial growth will be invaluable as Broken String advances its groundbreaking INDUCE-seq® technology, setting new standards for safety and precision in cell and gene therapy development. Broken String Biosciences has been a portfolio company of Merieux Equity Partners Innovation fund OMX Europe since August 2023. #Healthcare #Innovation #Governance #NextGenTherapies #PrecisionMedicine

At Merieux Equity Partners, driven by our #OneHealth approach, we recognize that #Biodiversity plays a fundamental role in maintaining ecosystems that directly impact human health. As we enter the European Week of Sustainable Development, we are thrilled to announce the publication of our Nature strategy, which outlines our commitment to preserving and enhancing biodiversity across all our operations and investments. Some key actions we have implemented to protect and promote biodiversity: 🌱 Integration of biodiversity into all our investment operations: each phase of the investment cycle, from acquisition to exit, now takes biodiversity criteria into account; 🍃 Ambitious goals for 2026 : we will identify the nature-related impacts and dependencies for 100% of our portfolio companies ♻️ Strengthening our internal policies: reduction of CO2 emissions through an optimized travel policy, enhanced waste management, and increased reuse of electronic equipment; 🔗 Alignment with the Global Biodiversity Framework: we are structuring our approach to align our investments with global biodiversity conservation goals and are committed to supporting the ecological transition; 🤝 Support for our portfolio companies: we assist our companies in building their biodiversity capacities and integrating sustainable practices. Click the following link to find out more about our Nature Strategy 🌿: https://lnkd.in/dDQptBtg Together, let’s make a difference 🌍 #Sustainability #ResponsibleInvestment #SEDD #EWSD #ESG

Merieux Equity Partners Innovation team is growing : we are thrilled to announce that Kristin Thompson has joined our team as Investment Director. Kristin was previously Chief Operating Officer at the private investment company eureKARE, where she contributed to 11 investments (notably in DNAScript, Coave Therapeutics, and Biomemory). She also created two start-up companies from academic tech transfer. Kristin was previously board member of companies (including eureKING and Gynov). Kristin started her career as a researcher for more than 10 years in academia (UNC-CH, Inserm) and worked closely with Boehringer Ingelheim and PTC Therapeutics. Her research always focused on novel modalities such as AAV and Lentivirus, CRISPR-Cas, and 3D cell systems. Following a successful stint as a researcher, Kristin transitioned to various roles in Business Development in France, working on topics such as in-and out licensing, corporate restructuring and strategic partnerships with Da Volterra, Famar (following acquisition by KKR) and Bioaster. Kristin Thompson holds degrees in Biology, specializing in genetics from the University of North Carolina at Chapel Hill, and a PhD in Molecular Medicine from the University of Ulm, Germany. As an American having worked in the US, Spain, Germany and France, Kristin will bring her deep knowledge of these markets and ecosystems to our portfolio companies and will help to facilitate their international development. Kristin was elected in 2022 as a finalist for the LSX Women’s European Business Leader award. #HiringAnnouncement #Leadership #Healthcare #Innovation #TeamExpansion

Merieux Equity Partners is thrilled to announce its investment in CorFlow, through its Innovation fund 1, OMX Europe, building a top tier international board of directors featuring investors from Mérieux Equity Partners, Broadview Ventures Inc, Panakes Partners, Laerdal Million Lives Fund, and 415 Capital. 🚀 CorFlow, a pioneering Swiss medical technology company, developing the CoFi system, the first integrated solution designed to diagnose and treat microvascular obstruction (MVO) during cathlab procedures, immediately following stent implantation. This innovative system combines a console, catheter set, and pressure wire, allowing for both diagnosis and treatment within a single procedure. This strategic investment will empower CorFlow to undertake a pivotal clinical trial aimed at validating initial positive results and securing market authorization in the United States. Additionally, an adaptive therapy study will be initiated to assess the effectiveness of localized therapeutics delivered via the CoFi system for heart attack patients suffering from MVO. Congratulations to the CorFlow teams and all partners for this significant achievement 👏 #CorFlow #STEMI #MVO #Precision #HeartAttack #MOCA

📆 IPEM Paris 2024 kicks off today! Over the next 3 days, Merieux Equity Partners will be taking part in conversations and events at IPEM and making the case for investing in Healthcare. We are excited to reconnect with our Limited Partners and expand our ecosystem. Interested in investing in Healthcare in Europe? Reach out to Thierry CHIGNON or Jean Chatillon. See you at IPEM! #IPEM2024 #PrivateEquity #Healthcare

#Nomination We are thrilled to announce that Jean-Guillaume Lafay is joining Merieux Equity Partners Innovation team as Operating Partner. Jean-Guillaume brings over 30 years of entrepreneurial experience, including more than 15 years in healthcare. He notably co-founded and served as CEO of Mablink (acquired by Eli Lilly), marking one of the best exits in the French healthcare space in 2023. He brings to Mérieux Equity Partners a deep expertise in the field of therapeutic platforms and life sciences. At Mérieux Equity Partners, Jean-Guillaume will play a key role in supporting our portfolio companies, focusing in particular on leadership, governance, HR, quality, traceability, and processes. His commitment to innovation, his energy and his human values will greatly contribute to our mission of investing in companies that accelerate access to products/services with transformative impact on patients. Link to the PR ➡ https://lnkd.in/dedYv_Ym